PLoS ONE (Jan 2021)

Women survive longer than men undergoing cytoreductive surgery and HIPEC for appendiceal cancer.

  • Noah S Rozich,
  • Samara E Lewis,
  • Sixia Chen,
  • Kenneth E Stewart,
  • Michael B Stout,
  • William C Dooley,
  • Laura E Fischer,
  • Katherine T Morris

DOI
https://doi.org/10.1371/journal.pone.0250726
Journal volume & issue
Vol. 16, no. 4
p. e0250726

Abstract

Read online

BackgroundWe hypothesize that women undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis from appendiceal cancer will have a survival advantage compared to men.MethodsThe National Cancer Database (NCDB) public user file (2004-2014) was used to select patients with PC undergoing CRS and HIPEC from appendiceal cancer. Univariate and multivariable analyses were performed.Results1,190 patients with PC from appendiceal cancer underwent HIPEC and CRS. OS was significantly longer for women than for men, with mean and median OS being 73.8 months and 98.2 months for women vs 58.7 months and 82.5 months for men, respectively (p = 0.0032). On multivariable analysis, male sex (HR: 1.444, 95% CI: 1.141-1.827, p = 0.0022) and increasing age (HR: 1.017, 95% CI: 1.006-1.027, p = 0.0017) were both found to be independent risk factors for worse OS.ConclusionWomen undergoing CRS and HIPEC for PC from appendiceal origin live longer than men undergoing the same treatment. Increasing age was also found to be independent risk factors for worse survival.